Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Dicyclomine
Drug ID BADD_D00659
Description Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder and irritable bowel syndrome.[A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may have been based on a small amount of evidence and so its prescription is becoming less favourable.[L7982] Dicyclomine was granted FDA approval on 11 May 1950.[L7967]
Indications and Usage including Colicky abdominal pain; diverticulitis
Marketing Status Prescription; Discontinued
ATC Code A03AA07
DrugBank ID DB00804
KEGG ID D07820
MeSH ID D004025
PubChem ID 3042
TTD Drug ID D07XJM
NDC Product Code Not Available
Synonyms Dicyclomine | Dicycloverin | Dicyclomine Hydrochloride | Hydrochloride, Dicyclomine | Merbentyl | Bentylol | Spascol | Di-Spaz | Di Spaz | Dibent | Diclomin | Lomine | OR-Tyl | OR Tyl | Bentyl | Di-Cyclonex | Di Cyclonex
Chemical Information
Molecular Formula C19H35NO2
CAS Registry Number 77-19-0
SMILES CCN(CC)CCOC(=O)C1(CCCCC1)C2CCCCC2
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Drug hypersensitivity10.01.01.0010.001232%Not Available
Dry mouth07.06.01.002--
Dysarthria19.19.03.001; 17.02.08.0010.000411%
Dyskinesia17.01.02.006--
Dyspepsia07.01.02.001--
Dyspnoea02.01.03.002; 22.02.01.004--
Erythema23.03.06.0010.000411%Not Available
Eye disorder06.08.03.001--Not Available
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.003--
Fatigue08.01.01.0020.000411%
Feeling abnormal08.01.09.014--Not Available
Gallbladder disorder09.03.02.0010.000821%Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal pain07.01.05.005--
Hallucination19.10.02.0020.000616%
Hallucination, visual19.10.02.004--Not Available
Headache17.14.01.0010.000411%
Hyperhidrosis23.02.03.004; 08.01.03.0280.000411%
Hypersensitivity10.01.03.0030.001232%
Hypertension24.08.02.001--
Hypoaesthesia17.02.06.023--Not Available
Hypohidrosis08.01.03.029; 23.02.03.005--
Immune system disorder10.02.01.001--Not Available
Injection site reaction12.07.03.015; 08.02.03.014--
Insomnia19.02.01.002; 17.15.03.002--
Irritable bowel syndrome19.24.01.003; 07.02.04.0030.000411%Not Available
Lethargy17.02.04.003; 08.01.01.008; 19.04.04.004--
Loss of consciousness17.02.04.004--Not Available
Malaise08.01.01.003--
Mania19.16.02.002--
The 2th Page    First    Pre   2 3 4    Next   Last    Total 4 Pages